pazopanib derivatives (Tianjin University)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namepazopanib derivatives (Tianjin University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor subunit A inhibitorsVascular endothelial growth factor receptor 2 antagonistsStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptorPlatelet-derived growth factor subunit AVascular endothelial growth factor receptor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTianjin University
China Registration ClassN/A

Develop Information

Active CompaniesTianjin University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A